Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics–Pharmacodynamics and Systems Pharmacology-Reference-Cited by-同舟云学术

Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics–Pharmacodynamics and Systems Pharmacology

Published:2024-01-17 Issue:2 Volume:7 Page:406-420
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Peng Jinfu¹²^ORCID,Huang Jie¹,Tan Hongyi¹,Kuang Yun¹,Yang Guoping¹²³^ORCID,Huang Zhijun¹³

Affiliation:

1. Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha 410013 Hunan, China

2. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410031 Hunan, China

3. National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008 Hunan, China

Funder

Natural Science Foundation of Hunan Province

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.3c00256

Reference36 articles.

1. The changing landscape of atherosclerosis

2. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

3. Recent advances in the pharmacological management of hypercholesterolaemia

4. A Receptor-Mediated Pathway for Cholesterol Homeostasis

5. PCSK9

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in physiologically based pharmacokinetic-pharmacodynamic models of amino acids in humans;Current Opinion in Clinical Nutrition & Metabolic Care;2024-08-05